Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258823 | 0.84 | HIF1A (0.75) | HIF1AABCB1CYP2D6ADRB2ADRB1 | |
| SCHEMBL16727482 | 0.78 | ABCB1 (0.70) | ABCB1ADRB2ADRB1ADRB3 | |
| SCHEMBL11850939 | 0.77 | ADRB2 (0.73) | ABCB1CYP2D6HTR2AHTR1AADRB2 | |
| SCHEMBL10336594 | 0.76 | NR2E1 (0.69) | ABCB1CYP2D6HTR2AHTR1AADRB2 | |
| SCHEMBL10805464 | 0.75 | CYP2D6 (0.74) | ABCB1CYP2D6HTR2AHTR1A | |
| SCHEMBL30001633 | 0.75 | CYP2D6 (0.74) | ABCB1CYP2D6HTR2AHTR1A | |
| SCHEMBL16727483 | 0.75 | ABCB1 (0.75) | ABCB1ADRB2ADRB1HTTADRB3 | |
| SCHEMBL8226025 | 0.74 | HTR1A (0.51) | HIF1AABCB1CYP2D6HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL10806395 | 0.74 | CYP2D6 (0.72) | ABCB1CYP2D6HTR2AHTR1A | |
| SCHEMBL8706577 | 0.73 | CYP2D6 (0.64) | ABCB1CYP2D6HTR2AADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | HIF1A 4311/4885ABCB1 50/4885CYP2D6 9/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | HIF1A 4311/4885ABCB1 50/4885CYP2D6 9/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | HIF1A 4527/4885ABCB1 59/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.